Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 4-factor prothrombin complex concentrate in complex cardiovascular surgery with cardiopulmonary bypass
jRCT2071250105Phase 3Recruiting
- Sponsor
- CSL Limited
- Start
- Apr 2026
- Modality
- Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of balfaxar in coagulopathy (2 arms), sponsored by CSL Limited. Primary endpoint: Successful correction of coagulation factor deficiency by INR. Started Apr 2026; status: recruiting.
02
Drugs
balfaxar
03
Conditions
coagulopathy
Beyond the preview
Go deeper on jRCT2071250105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250105.